Global Healthcare and Technology Leader Omar Ishrak Joins Insightec’s Board of Directors
HAIFA, Israel & MIAMI, June 1, 2022 /PRNewswire/ — Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care, today announced the appointment of Dr. Omar Ishrak to Insightec’s Board of Directors. Ishrak, widely recognized as a global visionary and thought leader, brings decades of deep expertise in healthcare and technology.
“Omar Ishrak has an impressive track record of strategic and forward-thinking leadership, and he shares our passion for improving the lives of patients through continuous innovation,” said Maurice R. Ferré, MD, Insightec CEO and President. from the administration board. “Omar is dedicated to healthcare transformation and Insightec is proud to welcome him to its Board of Directors.”
“I am honored to join the board of a growing medical technology company dedicated to innovating, disrupting and improving healthcare,” said Ishrak. “Insightec uses technology to help improve human well-being, and I look forward to contributing to these efforts.”
Ishrak, current Chairman of the Board of Intel Corporation, sits on the board of Amgen, Cargilland the Cleveland Clinic. Ishrak also sits on the board of the Asia Society and is a senior advisor to Blackstone Life Sciences.
Prior to joining Intel’s board of directors in 2017, Ishrak served as president and CEO of Medtronic from 2011 to 2020. From 1995 to 2011, Ishrak served as president and CEO of three GE Healthcare divisions: Systems , Clinical Systems and Ultrasound and BMD.
Ishrak, who earned his bachelor’s and doctorate degrees in electrical and electronic engineering from King’s College London, was elected a fellow by his alma mater in 2017 and is inducted into the National Academy of Engineering, the Bakken Society and the American Institute for Medical and College of Biological Engineering Fellows.
Insightec is a global healthcare company creating the next generation of patient care by realizing the therapeutic power of acoustic energy. The Company’s Exablate Neuro platform focuses sound waves, safely guided by MRI, to provide tremor treatment for patients with drug-refractory essential tremor and Parkinson’s disease. Research for future applications in the field of neuroscience is underway in partnership with leading academic and medical institutions. Insightec is headquartered in Haifa, Israeland Miami, with offices in Dallas, Shanghai and Tokyo.
Follow us on Facebook, LinkedIn and Twitter or visit www.insightec.com for more information.
This document contains forward-looking statements regarding, among other things, future plans, expectations and events. In some instances, forward-looking statements may be identified by the following words: “may”, “may”, “will”, “could”, “should”, “should”, “expect”, “has intention to”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “projects”, “potential”, “promises”, “continues”, “in progress” or the negative of these terms. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. Any forward-looking statement is based on information available to Insightec as of the date of the statement. All written or oral forward-looking statements attributable to Insightec are qualified by this cautionary statement. Insightec undertakes no obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Insightec’s expectations.
“Exablate” and “Exablate Neuro”, and the “INSIGHTEC” logo, whether alone or in combination with the word “Insightec”, are registered trademarks of Insightec.
Insightec media contact:
G&S Commercial Communications for Insightec
(312)648-6700 ext. 2108